Advances toward gene therapy for hemophilia at the millennium

Human Gene Therapy

Volumn 10, Issue 13, 1999, Pages 2091-2107

  Kaufman, Randal J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

GENE THERAPY; GENE TRANSFER; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; CLINICAL TRIALS; DNA, VIRAL; DOGS; FACTOR IX; FACTOR VIII; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MICE; VON WILLEBRAND FACTOR;

EID: 0033200188     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017095     Document Type: Review

References (102)

1. ADDIS, T. (1911). The pathogenesis of hereditary hemophilia. J. Pathol. Bacteriol. 15, 427-452.
2. AGARWALA, K.L., KAWABATA, S., TAKAO, T., MURATA, H., SHIMONISHI, Y., NISHIMURA, H., and IWANAGA, S. (1994). Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169. Biochemistry 33, 5167-5171.
3. ALEXEEV, V., and YOON, K. (1998). Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA. Nature Biotechnol. 16, 1343-1346.
4. AMANO, K., MICHNICK, D.A., MOUSSALLI, M., and KAUFMAN, R.J. (1998). Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: Implications for the APC resistance test. Thromb. Haemost. 79, 557-563.
5. ANTONARAKIS, S.E., ROSSITER, J.P., YOUNG, M., HORST, J., DE MOERLOOSE, P., SOMMER, S.S., KETTERLING, R.P., KAZAZIAN, H.H., JR., NEGRIER, C., and VINCIGUERRA, C. (1995). Factor VIII gene inversions in severe hemophilia A: Results of an international consortium study. Blood 86, 2206-2212.
6. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
7. BERNTORP, E. (1997). Second generation, B-domain deleted recombinant factor VIII. Thromb. Haemost. 78, 256-260.
8. BERTINA, R.M., KOELEMAN, B.P., KOSTER, T., ROSENDAAL, F.R., DIRVEN, R.J., DE RONDE, H., VAN DER VELDEN, P.A., and REITSMA, P.H. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (London) 369, 64-67.
9. BOND, M.D., HUBERTY, M.C., JANKOWSKI, M.A., VATH, J.E., STRANG, A.-M., and SCOBLE, H.A. (1997). Identification of O-glycosylation, sulfation and phosphorylation sites in the activation peptide of human plasma factor IX. Blood 84, 531a.
10. BONTEMPO, F.A., LEWIS, J.H., GOREC, T.J., SPERO, J.A., RAGNI, M.V., SCOTT, J.P., and STARZL, T.E. (1987). Liver transplantation in hemophilia A. Blood 69, 1721-1724.
11. BRANDSTETTER, H., BAUER, M., HUBER, R., LOLLAR, P., and BODE, W. (1995). X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B. Proc. Natl. Acad. Sci. U.S.A. 92, 9796-9800.
12. CAI, S.-R., KENNEDY, S.C., BOWLING, W.M., FLYE, M.W., and PONDER, K.P. (1998). Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy. J. Clin. Invest. 101, 2831-2841.
13. CHANG, J.L., JIN, J.P., STRAIGHT, D.L., and STAFFORD, D.W. (1998). Residues 330-338 in catalytic domain of factor IX represent an interactive site for both factor VIIIa and factor X. Blood 92, 184a.
14. CHOO, K.H., GOULD, K.G., REES, D.J., and BROWNLEE, G.G. (1982). Molecular cloning of the gene for human anti-haemophilic factor IX. Nature (London) 299, 178-180.
15. CONNELLY, S., GARDNER, J.M., LYONS, R.M., McCLELLAND, A., and KALEKO, M. (1996a). Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87, 4671-4677.
16. CONNELLY, S., GARDNER, J.M., McCLELLAND, A., and KALEKO, M. (1996b). High-level tissue-specific expression of functional human factor VIII in mice. Hum. Gene Ther. 7, 183-195.
17. CONNELLY, S., MOUNT, J., MAUSER, A., GARDNER, J.M., KALEKO, M., McCLELLAND, A., and LOTHROP, C.D., JR. (1996c). Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 88, 3846-3853.
18. CONNELLY, S., ANDREWS, J.L., GALLO, A.M., KAYDA, D.B., QIAN, J., HOYER, L., KADAN, M.J., GORZIGLIA, M.I., TRAPNELL, B.C., McCLELLAND, A., and KALEKO, M. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91, 3273-3281.
19. DAHLBACK, B. (1997). Resistance to activated protein C as risk factor for thrombosis: Molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol. 34, 217-234.
20. DAHLBACK, B., and HILDEBRAND, B. (1994). Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc. Natl. Acad. Sci. U.S.A. 91, 1396-1400.
21. DORNER, A.J., BOLE, D.G., and KAUFMAN, R.J. (1987). The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J. Cell. Biol. 105, 2665-2674.
22. DORNER, A.J., WASLEY, L.C., and KAUFMAN, R.J. (1990). Protein dissociation from GRP78 and secretion is blocked by depletion of cellular ATP levels. Proc. Natl. Acad. Sci. U.S.A. 87, 7429-7432.
23. FALLAUX, F.J., HOEBEN, R.C., CRAMER, S.J., VAN DEN WOLLENBERG, D.J., BRIET, E., VAN ORMONDT, H., and VAN DER EB, A.J. (1996). The human clotting factor VIII cDNA contains an autonomously replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression, and mediates the transcriptional effects of sodium butyrate. Mol. Cell. Biol. 16, 4264-4272.
24. FAY, P.J., and KOSHIBU, K. (1998). The A2 subunit of factor VIIIa modulates the active site of factor IXa. J. Biol. Chem. 273, 19049-19054.
25. FAY, P.J., and SMUDZIN, T.M. (1992). Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J. Biol. Chem. 267, 13246-13250.
26. FAY, P.J., HAIDARIS, P.J., and SMUDZIN, T.M. (1991). Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J. Biol. Chem. 266, 8957-8962.
27. FAY, P.J., BEATTIE, T., HUGGINS, C.F., and REGAN, L.M. (1994). Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J. Biol. Chem. 269, 20522-20527.
28. GACZYNSKA, M., GOLDBERG, A.L., TANAKA, K., HENDIL, K.B., and ROCK, K.L. (1996). Proteasome subunits X and Y alter peptides activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. J. Biol. Chem. 271, 17275-17280.
29. GIRMA, J.P., FRESSINAUD, E., HOULLIER, A., LAURIAN, Y., AMIRAL, J., and MEYER, D. (1998). Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. Haemophilia 4, 98-103.
30. HERZOG, R.W., and HIGH, K.A. (1998). Problems and prospects in gene therapy for hemophilia. Curr. Opin. Hematol. 5, 321-326.
31. HERZOG, R.W., YANG, E.Y., COUTO, L.B., HAGSTROM, J.N., ELWELL, D., FIELDS, P.A., BURTON, M., BELLINGER, D.A., READ, M.S., BRINKHOUS, K.M,. PODSAKOFF, G.M., NICHOLS, T.C., KURTZMAN, G.J., and HIGH, K.A. (1999). Longterm correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med. 5, 56-63.
32. HILL-EUBANKS, D.C., PARKER, C.G., and LOLLAR, P. (1989). Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc. Natl. Acad. Sci. U.S.A. 86, 6508-6512.
33. HOEBEN, R.C., VAN DER JAGT, R.C., SCHOUTE, F., VAN TILBURG, N.H., VERBEET, M.P., BRIET, E., VAN ORMONDT, H., and VAN DER EB, A.J. (1990). Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J. Biol. Chem. 265, 7318-7323.
34. JENNY, R.J., PITTMAN, D.D., TOOLE, J.J., KRIZ, R.W., ALDAPE, R.A., HEWICK, R.M., KAUFMAN, R.J., and MANN, K.G. (1987). Complete cDNA and derived amino acid sequence of human factor V. Proc. Natl. Acad. Sci. U.S.A. 84, 4846-4850.
35. JOOSS, K., YANG, Y., FISHER, K.J., and WILSON, J.M. (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72, 4212-4223.
36. KAUFMAN, R.J. (1998). Post-translational modifications required for coagulation factor secretion and function. Thromb. Haemost. 12, 1812-1824.
37. KAUFMAN, R.J., WASLEY, L.C., and DORNER, A.J. (1988). Synthesis processing and secretion of factor VIII expressed in mammalian cells. J. Biol. Chem. 263, 6352-6362.
38. KAUFMAN, R.J., WASLEY, L.C., DAVIES, M.V., WISE, R.J., and ISRAEL, D.I. (1989). The effect of von Willebrand factor co-expression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol. Cell. Biol. 9, 1233-1242.
39. KAUFMAN, R.J., DORNER, A.J., and FASS, D.N. (1999). von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver. Blood 93, 193-197.
40. KAY, M.A., LANDEN, C.N., ROTHENBERG, S.R., TAYLOR, L.A., LELAND, F., WIEHLE, S., FANG, B., BELLINGER, D., FINEGOLD, M., and THOMPSON, A.R. (1994). In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemohilia B dogs. Proc. Natl. Acad. Sci. U.S.A. 91, 2353-2357.
41. KELLY, D.A., SUMMERFIELD, J.A., and TUDDENHAM, E.G. (1984). Localization of factor VIIIC: Antigen in guinea-pig tissues and isolated liver cell fractions. Br. J. Haematol. 56, 535-543.
42. KOEBERL, D.D., HALBERT, C.L., KRUMM, A., and MILLER, A.D. (1995). Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum. Gene Ther. 6, 469-479.
43. KOEBERL, D.D., ALEXANDER, I.E., HALBERT, C.L., RUSSELL, D.W., and MILLER, A.D. (1997). Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A. 94, 1426-1431.
44. KOSIK, K.S., and FURIE, B. (1980). Thrombotic stroke associated with elevated plasma factor VIII. Ann. Neurol. 8, 435-437.
45. KOSTER, T., BLANN, A.D., BRIET, E., VANDENBROUCKE, J.P., and ROSENDAAL, F.R. (1995). Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155.
46. KREN, B.T., BANDYOPADHYAY, P., and STEER, C.J. (1998). In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nature Med. 4, 285-290.
47. KURACHI, K., and DAVIE, E.W. (1982). Isolation and characterization of a cDNA coding for human factor IX. Proc. Natl. Acad. Sci. U.S.A. 79, 6461-6464.
48. LAKICH, D., KAZAZIAN, H.H., ANTONARAKIS, S.E., and GITSCHIER, J. (1993). Inversions disrupting the factor VIII gene as a common cause of severe hemophilia A. Nature Genet. 5, 236-241.
49. LANE, S. (1840). Haemorrhagid diathesis. Successful transfusion of blood. Lancet 1, 185-188.
50. LENTING, P.J., VAN DE LOO, J.W., DONATH, M.J., VAN MOURIK, J.A., and MERTENS, K. (1996). The sequence of Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J. Biol. Chem. 271, 1935-1940.
51. LEWIS, J.H., BONTEMPO, F.A., SPERO, J.A., RAGNI, M.V., and STARZL, T.E. (1985). Liver transplantation in a hemophiliac. N. Engl. J. Med. 312, 1189-1190.
52. LIU, L., XIA, S., and SEIFERT, J. (1994). Transplantation of spleen cells in patients with hemophilia A. A report of 20 cases. Transplant. Int. 7, 201-206.
53. LOLLAR, P. (1997). Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb. Haemost. 78, 647-651.
54. LOLLAR, P., and PARKER, C.G. (1987). Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 28, 666-674.
55. LOLLAR, P., and PARKER, C.G. (1990). pH-dependent denaturation of tnrombin-activated porcine factor VIII. J. Biol. Chem. 265, 1688-1692.
56. LOLLAR, P., and PARKER, C.G. (1991). Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J. Biol. Chem. 265, 12481-12486.
57. LOZIER, J.N., METZGER, M.E., DONAHUE, R.E., and MORGAN, R.A. (1999). The rhesus macaque as an animal model for hemophilia B gene therapy. Blood 93, 1875-1881.
58. LUSHER, J.M. (1997). Prophylaxis in children with hemophilia: Is it the optimal treatment? Thromb. Haemost. 78, 726-729.
59. LYNCH, C.M., ISRAEL, D.I., KAUFMAN, R.J., and MILLER, A.D. (1993). Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum. Gene Ther. 4, 259-272.
60. MANNUCCI, P.M. (1988). Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 72, 1449-1455.
61. MANNUCCI, P.M., TENCONI, P.M., CASTAMAN, G., and RODEGHIERO, F. (1992). Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial. Blood 79, 3130-3137.
62. MARQUETTE, K.A., PITTMAN, D.D., and KAUFMAN, R.J. (1995). A 110 amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J. Biol. Chem. 270, 10297-10303.
63. MATHUR, A., and BAJAJ, S.P. (1999). Protease and EGF1 domains of factor IXa. J. Biol. Chem. 274, 18477-18486.
64. MICHNICK, D.A., PITTMAN, D.D., and KAUFMAN, R.J. (1993). Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J. Biol. Chem. 269, 20095-20102.
65. MOHLKE, K., PURKAYASTHA, A., WESTERICK, R., SMITH, P., PETRYNIAK, B., LOWE, J., and GINSBURG, D. (1999). Mvwf, A dominant modifier of murine von Willebrand factor: Results from altered lineage-specific expression of a glycosyltransferase. Cell 96, 111-120.
66. MONAHAN, P.E., SAMULSKI, R.J., TAZELAAR, J., XIAO, X., NICHOLS, T.C., BELLINGER, D.A., READ, M.S., and WALSH, C.E. (1998). Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. 5, 40-49.
67. MUSTAFA, R.L., ELWELL, D.R., RUSSELL, K.E., NICHOLS, T.C., and READ, M.S. (1998). A role for whole blood clotting time as a sensitive screening test for F. VIII and F. IX replacement. Blood 92, 96a.
68. NAKAI, H., HERZOG, R.W., HAGSTROM, J.N., WALTER, J., KUNG, S.H., YANG, E.Y., TAI, S.J., IWAKI, Y., KURTZMAN, G.J., FISHER, K.J., COLOSI, P., COUTO, L.B., and HIGH, K.A. (1998). Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91, 4600-4607.
69. NISHIMURA, H., TAKAO, T., HASE, S., SHIMONISHI, Y., and IWANAGA, S. (1992). Human factor IX has a tetrasaccharide O-glycosidically linked to serine 61 through the fucose residue. J. Biol. Chem. 267, 17520-17525.
70. NORDFANG, O., and EZBAN, M. (1988). Generation of active coagulation factor VIII from isolated subunits. J. Biol. Chem. 263, 1115-1118.
71. OTTO, J.E. (1803). An account of an hemorrhagic disposition existing in certain families. Med. Repository 6, 1.
72. OVER, J., SIXMA, J.J., BRUINE, M.H., TRIESCHNIGG, M.C., VLOOSWIJK, R.A., BEESER-VISSER, N.H., and BOUMA, B.N. (1978). Survival of 125 iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J. Clin. Invest. 62, 223-234.
73. PATEK, A.J., and TAYLOR, F.H.L. (1937), Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J. Clin. Invest. 16, 113-124.
74. PELLEQUER, J.L., GALE, A.J., GRIFFIN, J.H., and GETZOFF, E.D. (1998). Homology models of the C domains of blood coagulation factors V and VIII: A proposed membrane binding mode for FV and FVIII C2 domains. Blood Cells Mol. Dis. 24, 448-461.
75. PEMBERTON, S.. LINDLEY, P., ZAITSEV, V., CARD, G., TUDDENHAM, E.G.D., and KEMBALL-COOK, G. (1997). A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 89, 2413-2421.
76. PIPE, S.W., and KAUFMAN, R.J. (1997). Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc. Natl. Acad. Sci. U.S.A. 94, 11851-11856.
77. PIPE, S.W., MORRIS, J.A., SHAH, J., and KAUFMAN, R.J. (1998). Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J. Biol. Chem. 273, 8537-8544.
78. PIPE, S.W., EICKHORST, A.N., MCKINLEY, E.L., SAENKO, E.L., and KAUFMAN, R.J. (1999). Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: Evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 93, 176-183.
79. PITTMAN, D.D., and KAUFMAN, R.J. (1988). The proteolytic requirements for activation and inactivation of antihemophilic factor (factor VIII). Proc. Natl. Acad. Sci. U.S.A. 85, 2429-2433.
80. PITTMAN, D.D., ALDERMAN, E.A., TOMKINSON, K.N., WANG, J.H., GILES, A.R., and KAUFMAN, R.J. (1993). Biochemical, immunological, and in vivo functional characterization of B-domain deleted factor VIII. Blood 81, 2925-2935.
81. REGAN, L.M., and FAY, P.J. (1995). Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J. Biol. Chem. 270, 8546-8552.
82. ROSENBERG, J.B., FOSTER, P.A., KAUFMAN, R.J., VOKAC, E.A., MOUSSALLI, M., KRONER, P.A., and MONTGOMERY, R.R. (1997). Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J. Clin. Invest. 101, 613-624.
83. ROSNER, F. (1969). Hemophilia in the Talmud and rabbinic writings. Ann. Intern. Med. 70, 833-837.
84. RUSSELL, K.E., NICHOLS, T.C., ELWELL, D.R., BELLINGER, D.A., RUP, B.J., KEITH, J.C., LEITERMANN, K., MCCARTHY, K.P., SCHAUB, R.G., and READ, M.S. (1998). Maintenance of immune tolerance in hemophilia B dogs by subcutaneous administration of recombinant human factor IX (Benefix). Blood 92, 554a.
85. SCANDELLA, D., MATTINGLY, M., DE GRAAF, S., and FULCHER, C.A. (1989). Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 74, 1618-1626.
86. SNYDER, R.O., MIAO, C.H., PATIJN, G.A., SPRATT, S.K., DANOS, O., NAGY, D., GOWN, A.M., WINTHER, B., MEUSE, L., COHEN, L.K., THOMPSON, A.R., and KAY, M.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet. 16, 270-276.
87. SNYDER, R.O., MIAO, C., MEUSE, L., TUBE, J., DONAHUE, B.A., LIN, H.F., STAFFORD, D.W., PATEL, S., THOMPSON, A.R., NICHOLS, T., READ, M.S., BELLINGER, D.A., BRINKHOUS, K.M., and KAY, M.A. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med. 5, 64-70.
88. STUBBS, J.D., LEKUTIS, C., SINGER, K.L., BUI, A., YUZUKI, D., SRINIVASAN, U., and PARRY, G. (1990). cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. Proc. Natl. Acad. Sci. U.S.A. 87, 8417-8421.
89. SWAROOP, M., MOUSSALLI, M., PIPE, S.W., and KAUFMAN, R.J. (1997). Mutagenesis of a potential BiP binding site enhances secretion of coagulation factor VIII. J. Biol. Chem. 272, 24121-24124.
90. TAGLIAVACCA, L., MOON, N., DUNHAM, W.R., and KAUFMAN, R.J. (1997). Identification and functional requirement of Cu(II) and its ligands within coagulation factor VIII. J. Biol. Chem. 272, 27428-27434.
91. TOOLE, J.J., KNOPF, J.L., WOZNEY, J.M., SULTZMAN, L.A., BUECKER, J.L., PITTMAN, D.D., KAUFMAN, R.J., BROWN, E., SHOEMAKER, C., and ORR, E.C. (1984). Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature (London) 312, 342-347.
92. WANG, L., TAKABE, K., BIDLINGMAIER, S.M., ILL, C.R., and VERMA, I. (1999). Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc. Natl. Acad. Sci. U.S.A. 96, 3906-3910.
93. WASLEY, L.C., REHEMTULLA, A., BRISTOL, J.A., and KAUFMAN, R.J. (1993). PACE/furin processes the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J. Biol. Chem. 268, 8458-8465.
94. WEISS, H.J., SUSSMAN, I.I., and HOYER, L.W. (1977). Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J. Clin. Invest. 60, 390-404.
95. WHITE, G.C., DIMICHELE, D., MERTENS, K., NEGRIER, C., PEAKE, I.R., PROWSE, C., SCHWAAB, R., YOSHIOKA, A., and INGERSLEV, J. (1999). Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. 81, 462.
96. WION, K.L., KELLY, D., SUMMERFIELD, J.A., TUDDENHAM, E.G.D., and LAWN, R.M. (1985). Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature (London) 317, 726-729.
97. WISE, R.J., DORNER, A.J., KRANE, M., PITTMAN, D.D., and KAUFMAN, R.J. (1991). The role of von Willebrand factor multimerization and propeptide cleavage in the binding and stabilization of factor VIII. J. Biol. Chem. 266, 21948-21955.
98. WOOD, W.I., CAPON, D.J., SIMONSEN, C.C., EATON, D.L., GITSCHIER, J., KEYT, B., SEEBURG, P.H., SMITH, D.H., HOLLINGSHEAD, P., WION, K.L., DELWART, E., TUDDENHAM, E.G.D., VEHAR, G.A., and LAWN, R.M. (1984). Expression of active human factor VIII from recombinant DNA cloned. Nature (London) 312, 330-337.
99. YANG, Y., JOOSS, K.U., SU, Q., ERTL, H.C., and WILSON, J.M. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
100. YE, X., GAO, G.P., PABIN, C., RAPER, S.E., and WILSON, J.M. (1998). Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum. Gene Ther. 9, 2135-2142.
101. YOSHITAKE, S., SCHACH, B.G., FOSTER, D.C., DAVIE, E.W., and KURACHI, K. (1985). Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 24, 3736-3750.
102. ZELECHOWSKA, M.G., VAN MOURIK, J.A., and BRODNIEWICZPROBA, T. (1985). Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature (London) 317, 729-730.